Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2022)

Top diagnostic & research stocks in 2022 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

Sotera Health Co (NASDAQ:SHC) is the top diagnostic & research stock with a Zen Score of 61, which is 27 points higher than the diagnostic & research industry average of 34. It passed 20 out of 33 due diligence checks and has strong fundamentals. Sotera Health Co has seen its stock lose -72.5% over the past year, underperforming other diagnostic & research stocks by -34 percentage points.

Sotera Health Co has an average 1 year price target of $19.33, an upside of 168.14% from Sotera Health Co's current stock price of $7.21.

Sotera Health Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 7 analysts covering Sotera Health Co, 0% have issued a Strong Buy rating, 14.29% have issued a Buy, 71.43% have issued a hold, while 0% have issued a Sell rating, and 14.29% have issued a Strong Sell.

Medpace Holdings (NASDAQ:MEDP) is the second best diagnostic & research stock with a Zen Score of 59, which is 25 points higher than the diagnostic & research industry average of 34. It passed 20 out of 33 due diligence checks and has strong fundamentals. Medpace Holdings has seen its stock lose -22.68% over the past year, overperforming other diagnostic & research stocks by 16 percentage points.

Medpace Holdings has an average 1 year price target of $142.00, a downside of -3.87% from Medpace Holdings's current stock price of $147.71.

Medpace Holdings stock has a consensus Sell recommendation according to Wall Street analysts. Of the 2 analysts covering Medpace Holdings, 0% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 50% have issued a Strong Sell.

Syneos Health (NASDAQ:SYNH) is the third best diagnostic & research stock with a Zen Score of 57, which is 23 points higher than the diagnostic & research industry average of 34. It passed 18 out of 33 due diligence checks and has strong fundamentals. Syneos Health has seen its stock lose -49.59% over the past year, underperforming other diagnostic & research stocks by -11 percentage points.

Syneos Health has an average 1 year price target of $88.14, an upside of 85.1% from Syneos Health's current stock price of $47.62.

Syneos Health stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Syneos Health, 44.44% have issued a Strong Buy rating, 11.11% have issued a Buy, 44.44% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 9 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Koninklijke Philips Nv (NYSE:PHG) has an annual dividend yield of 6.21%, which is 5 percentage points higher than the diagnostic & research industry average of 1.71%. Koninklijke Philips Nv's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Koninklijke Philips Nv's dividend has not shown consistent growth over the last 10 years.

Koninklijke Philips Nv's dividend payout ratio of 24.8% indicates that its high dividend yield is sustainable for the long-term.

Psychemedics (NASDAQ:PMD) has an annual dividend yield of 3.08%, which is 1 percentage points higher than the diagnostic & research industry average of 1.71%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -57.1% indicates that its dividend yield might not be sustainable for the long-term.

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.08%, which is the same as the diagnostic & research industry average of 1.71%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 20.8% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were down -1.17% in the last day, and down -6.9% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

Syneos Health (NASDAQ:SYNH) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Syneos Health has a valuation score of 86, which is 49 points higher than the diagnostic & research industry average of 37. It passed 6 out of 7 valuation due diligence checks.

Syneos Health's stock has dropped -49.59% in the past year. It has underperformed other stocks in the diagnostic & research industry by -11 percentage points.

Sotera Health Co (NASDAQ:SHC) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Sotera Health Co has a valuation score of 86, which is 49 points higher than the diagnostic & research industry average of 37. It passed 6 out of 7 valuation due diligence checks.

Sotera Health Co's stock has dropped -72.5% in the past year. It has underperformed other stocks in the diagnostic & research industry by -34 percentage points.

Quidelortho (NASDAQ:QDEL) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Quidelortho has a valuation score of 86, which is 49 points higher than the diagnostic & research industry average of 37. It passed 6 out of 7 valuation due diligence checks.

Quidelortho's stock has dropped -49.01% in the past year. It has underperformed other stocks in the diagnostic & research industry by -10 percentage points.